Skip to main content

Table 4 Frequency of symptoms among patients using a DuoBaby nebulizer equipped (cases, n = 43) or not equipped (controls; n = 46) with a nasal aspiratora

From: The impact of nasal aspiration with an automatic device on upper and lower respiratory symptoms in wheezing children: a pilot case-control study

  Cases n = 43 Controls n = 46 pb
Mediana IQR Mediana IQR
Nasal symptoms in the last 24 h 25.0 (14.5–43.6) 46.4 (27.4–58.4) 0.004
 Runny nose 21.0 (10.6–37.3) 39.5 (22.5–48.3) 0.021
 Stuffy nose 15.3 (6.4–32.1) 24.0 (7.5–44.6) 0.160
 Mucus 14.4 (3.4–34) 21.1 (7.1–38.3) 0.289
 Crusts 1.5 (0–15.6) 6.7 (0–20.1) 0.485
Bronchial symptoms in the last 24 h 21.8 (14.5–37.3) 32.8 (16.8–50.3) 0.022
 Dry cough 12.7 (3.5–25.8) 17.8 (5.8–32.1) 0.229
 Productive cough 14.7 (6.5–18.9) 20.3 (9.3–37.7) 0.033
 Wheezing 3.6 (0–10.3) 2.6 (0–10.8) 1.000
 Difficult breathing 0.0 (0–3.3) 0.0 (0–3) 0.836
Fever 3.1 (0.8–5.3) 4.2 (1.6–6.9) 0.152
Sore throat 1.4 (0–3.2) 0.7 (0–4.3) 0.800
Earache 0.0 (0–1.2) 0.0 (0–2.2) 0.105
Hoarseness 0.8 (0–4.1) 0.4 (0–1.8) 0.342
Sleep disorders 6.0 (2.2–12) 6.3 (2.4–14.9) 0.690
Loss of appetite 3.2 (0–8.2) 3.1 (0.9–6.7) 0.747
Anxiety / restlessness 2.0 (0–4.7) 1.0 (0–6.6) 0.537
  1. aMedian (IQR) of the percentages of days with symptoms calculated at individual level (see method for definition)
  2. bMann Whitney U test was used to compare quantitative not normally distributed variables between groups (Shapiro-Wilk test was used to assess normality of data)
  3. Values marked in bold indicate statistically significant results with a p value < 0.05